Preeclampsia Screening Trial to Improve Outcomes (PRESTO)
Preeclampsia Screening Trial to Improve Outcomes: A Pre and Post Cohort Trial to Evaluate the Use of sFlt-1/PlGF Ratio in Women With Hypertensive Disorders of Pregnancy
The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies.
The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
详细说明
Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and delivery.
Participants assigned to Phase A - the control phase, will not have their lab results shared with their doctor and will receive standard care. Participants assigned to Phase B - the intervention phase, will have their lab results shared with their doctor. Following phase A but before phase B, clinicians will receive education on the blood test and clinical management.
Participation lasts from hospital enrollment through delivery and discharge. Newborns will not undergo study procedures, but information will be collected from their medical records for them. The blood samples from the single lab draw will be stored temporarily for study analysis only and will not be banked for future unspecified research. No experimental drugs will be administered.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习联系方式
学习联系方式
- 姓名:Tae Stallworth
- 电话号码:770-742-8942 |
- 邮箱:tae.stallworth@emory.edu
学习地点
-
-
Georgia
-
Decatur、Georgia、美国、30033
- Emory Decatur Hospital
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Pregnant persons aged 18 years or older.
- Singleton pregnancy.
- Gestational age from 23 weeks 0 days through 33 weeks 6 days.
- Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy.
- Provision of signed informed consent (English- or Spanish-speaking).
Exclusion Criteria:
- Enrollment in another therapeutic interventional trial with a primary outcome of HDP
- Receipt of intravenous heparin during hospitalization.
- Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate plan for delivery, but then a delivery decision is made, patients will still be included and analyzed accordingly)
- Prior study enrollment during the current pregnancy.
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
有源比较器:Blinded Test Results (Phase A)
Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study. Management proceeds per local standard of care. Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes. |
Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.
其他名称:
|
|
实验性的:Real Time Results (Phase B)
Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study. During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test. |
Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.
其他名称:
sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pregnancy latency
大体时间:At delivery (up to 40 weeks of gestation)
|
Time from admission to delivery |
At delivery (up to 40 weeks of gestation)
|
|
Participants with maternal adverse outcomes
大体时间:From enrollment until post-natal discharge (on average 10 days post-delivery)
|
The number of participants who experience one or more of the following maternal adverse events: cerebral hemorrhage, seizures (eclampsia), pulmonary edema, disseminated intravascular coagulation (DIC), new onset acute renal failure (creatinine > 1.4), peripartum cardiomyopathy, ischemic stroke, or HELLP syndrome [doubling of liver function test (LFT) and platelets count<100,000] or severe hypertension that required a parenteral infusion of a third-line antihypertensive. |
From enrollment until post-natal discharge (on average 10 days post-delivery)
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants who require hospital admission
大体时间:From enrollment up to 37 weeks of gestation
|
Number of participants who require hospital admission during study participation, collected form medical records. |
From enrollment up to 37 weeks of gestation
|
|
Number of participants with indicated delivery within 14 days of presentation
大体时间:Up to 14 days from enrollment
|
Participants who require delivery within 14 days of presentation |
Up to 14 days from enrollment
|
|
Number of participants who require transfer to tertiary care centers
大体时间:From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
|
Participants who require transfer to tertiary care centers as documented in the medical records. |
From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
|
|
Number of participants who received antenatal corticosteroid administration
大体时间:Between 24 weeks and 34 weeks of gestation
|
Participants who receive antenatal corticosteroid administration as documented in the medical records. |
Between 24 weeks and 34 weeks of gestation
|
|
Number of preterm births less than 37 weeks
大体时间:From enrollment up to 36 weeks and 6 days of pregnancy
|
Preterm births at <37 weeks' gestation between the pre-implementation and post-implementation periods. |
From enrollment up to 36 weeks and 6 days of pregnancy
|
|
Number of early preterm births
大体时间:From enrollment up to 31 weeks and 6 days of pregnancy
|
Early preterm births at <32 weeks' gestation between the pre-implementation and post-implementation periods. Analyses of preterm birth <32 weeks will be restricted to individuals enrolled before 32 weeks' gestation. |
From enrollment up to 31 weeks and 6 days of pregnancy
|
|
Composite Adverse Fetal/Neonatal Outcomes
大体时间:From maternal enrollment through 28 days after birth
|
Composite outcome defined as the occurrence of one or more of the following fetal or neonatal adverse events: fetal or neonatal death, low birth weight (<2500 g), respiratory distress syndrome (RDS), bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or grade III/IV intraventricular hemorrhage. The proportion of participants experiencing the composite outcome will be compared between the intervention and control groups. |
From maternal enrollment through 28 days after birth
|
|
Length of hospital admission (mother's) of stay,
大体时间:From admission until post-natal hospital discharge (on average 10 days post-delivery)
|
Length of hospital admission, extracted from medical records |
From admission until post-natal hospital discharge (on average 10 days post-delivery)
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Suchitra Chandrasekaran, MD、Emory University
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- 2026P000788
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual de-identified participant data may be made available upon reasonable request, subject to Sponsor review.
The specific data to be shared will be determined based on the Sponsor's review of the requested data and the nature of the request.
IPD 共享时间框架
No specific end date has been established.
IPD 共享访问标准
Requests will be reviewed by the Research Team, and approved data will be shared through a method determined Requests will be reviewed by the Sponsor, and approved data will be shared through an appropriate method determined at the time of approval. Data will be shared with the Qualified researchers or organizations whose requests are approved by the Sponsor. Contingent upon the Sponsor's approved data request.
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.